World Library  


Add to Book Shelf
Flag as Inappropriate
Email this Book

Plos One : Monitoring Monoclonal Antibody Delivery in Oncology ; the Example of Bevacizumab, Volume 8

By Rota, Rossella

Click here to view

Book Id: WPLBN0003963427
Format Type: PDF eBook :
File Size:
Reproduction Date: 2015

Title: Plos One : Monitoring Monoclonal Antibody Delivery in Oncology ; the Example of Bevacizumab, Volume 8  
Author: Rota, Rossella
Volume: Volume 8
Language: English
Subject: Journals, Science, Medical Science
Collections: Periodicals: Journal and Magazine Collection
Historic
Publication Date:
Publisher: Plos

Citation

APA MLA Chicago

Rota, R. (n.d.). Plos One : Monitoring Monoclonal Antibody Delivery in Oncology ; the Example of Bevacizumab, Volume 8. Retrieved from http://netlibrary.net/


Description
Description : Developing therapeutic monoclonal antibodies paves the way for new strategies in oncology using targeted therapy which should improve specificity. However, due to a lack of biomarkers, a personalized therapy scheme cannot always be applied with monoclonal antibodies. As a consequence, the efficacy or side effects associated with this type of treatment often appear to be sporadic. Bevacizumab is a therapeutic monoclonal antibody targeting Vascular Endothelial Growth Factor (VEGF). It is used to limit tumor vascularization. No prognosis or response biomarker is associated with this antibody, we therefore assessed whether the administration protocol could be a possible cause of heterogeneous responses (or variable efficacy). To do this, we developed a bevacizumab assay with a broad sensitivity range to measure blood bevacizumab concentrations. We then analyzed bevacizumab concentrations in 17 patients throughout the first quarter of treatment. In line with previously published data, average blood concentrations were 88+/227 mg/L following the first dose administered, and 213+/2105 mg/L after the last (6th) dose administered. However, the individual values were scattered, with a mean 4-fold difference between the lowest and the highest concentration for each dose administered. We demonstrated that the bevacizumab administration schedule results in a high inter-individual variability in terms of blood concentrations. Comparison of assay data with clinical data indicates that blood concentrations above the median are associated with side effects, whereas values below the median favor inefficacy. In conclusion, bevacizumab-based therapy could benefit from a personalized administration schedule including follow-up and adjustment of circulating bevacizumab concentrations.

 

Click To View

Additional Books


  • Plos One : Detailed Dimethylacetal and F... (by )
  • Plos One : Resveratrol Metabolites Modif... (by )
  • Plos One : Do Global Diversity Patterns ... (by )
  • Plos One : Müller Cell Reactivity in Res... (by )
  • Plos One : Why Herd Size Matters – Mitig... (by )
  • Plos One : Oral Microbiome of Deep and S... (by )
  • Plos One : Impact of Implementing Eviden... (by )
  • Plos One : Low Bone Strength is a Manife... (by )
  • Plos One : Long Qt Interval in Turner Sy... (by )
  • Plos One : Effect of Fruit Juice on Chol... (by )
  • Plos One : Gene Expression Patterns of H... (by )
  • Plos One : Only Missense Mutations Affec... (by )
Scroll Left
Scroll Right

 



Copyright © World Library Foundation. All rights reserved. eBooks from World Library are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.